281 related articles for article (PubMed ID: 23846172)
21. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.
Mani H; Hesse C; Stratmann G; Lindhoff-Last E
Thromb Haemost; 2013 Jan; 109(1):127-36. PubMed ID: 23138190
[TBL] [Abstract][Full Text] [Related]
22. Is anti-factor Xa chromogenic assay for Rivaroxaban appropriate in clinical practice? Advantages and comparative drawbacks.
Bardy G; Fischer F; Appert A; Baldin B; Stève M; Spreux A; Lavrut T; Drici MD
Thromb Res; 2015 Aug; 136(2):396-401. PubMed ID: 26058941
[TBL] [Abstract][Full Text] [Related]
23. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
[TBL] [Abstract][Full Text] [Related]
24. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.
Asmis LM; Alberio L; Angelillo-Scherrer A; Korte W; Mendez A; Reber G; Seifert B; Stricker H; Tsakiris DA; Wuillemin WA
Thromb Res; 2012 Apr; 129(4):492-8. PubMed ID: 21840043
[TBL] [Abstract][Full Text] [Related]
25. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.
Molenaar PJ; Dinkelaar J; Leyte A
Clin Chem Lab Med; 2012 Oct; 50(10):1799-807. PubMed ID: 23089710
[TBL] [Abstract][Full Text] [Related]
26. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
[TBL] [Abstract][Full Text] [Related]
27. Comparison of methods to determine rivaroxaban anti-factor Xa activity.
Rathbun S; Tafur A; Grant R; Esmon N; Mauer K; Marlar RA
Thromb Res; 2015 Feb; 135(2):394-7. PubMed ID: 25476589
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial.
Samama MM; Contant G; Spiro TE; Perzborn E; Flem LL; Guinet C; Gourmelin Y; Martinoli JL;
Clin Appl Thromb Hemost; 2012; 18(2):150-8. PubMed ID: 22387577
[TBL] [Abstract][Full Text] [Related]
30. Measurement of rivaroxaban concentrations demonstrates lack of clinical utility of a PT, dPT and APTT test in estimating levels.
Thom I; Cameron G; Robertson D; Watson HG
Int J Lab Hematol; 2018 Aug; 40(4):493-499. PubMed ID: 29718586
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Korostelev M; Bihan K; Ferreol L; Tissot N; Hulot JS; Funck-Brentano C; Zahr N
J Pharm Biomed Anal; 2014 Nov; 100():230-235. PubMed ID: 25173108
[TBL] [Abstract][Full Text] [Related]
32. Determination of rivaroxaban in human plasma samples.
Harenberg J; Erdle S; Marx S; Krämer R
Semin Thromb Hemost; 2012 Mar; 38(2):178-84. PubMed ID: 22422332
[TBL] [Abstract][Full Text] [Related]
33. Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization.
Wiesen MHJ; Blaich C; Taubert M; Jennissen V; Streichert T; Pfister R; Michels G
Eur J Clin Pharmacol; 2018 May; 74(5):611-618. PubMed ID: 29376194
[TBL] [Abstract][Full Text] [Related]
34. Correlating prothrombin time with plasma rivaroxaban level.
Rodgers R; Bagot CN; Lawrence C; Hickman G; McGurk M; Tait RC
Br J Haematol; 2013 Dec; 163(5):685-7. PubMed ID: 24219334
[No Abstract] [Full Text] [Related]
35. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
[TBL] [Abstract][Full Text] [Related]
36. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation.
Miklič M; Mavri A; Vene N; Söderblom L; Božič-Mijovski M; Pohanka A; Antovic J; Malmström RE
Eur J Clin Pharmacol; 2019 Aug; 75(8):1069-1075. PubMed ID: 31139866
[TBL] [Abstract][Full Text] [Related]
37. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
[TBL] [Abstract][Full Text] [Related]
38. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban.
Harenberg J; Marx S; Krämer R; Giese C; Weiss C
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):637-41. PubMed ID: 21986465
[TBL] [Abstract][Full Text] [Related]
39. Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS).
Derogis PB; Sanches LR; de Aranda VF; Colombini MP; Mangueira CL; Katz M; Faulhaber AC; Mendes CE; Ferreira CE; França CN; Guerra JC
PLoS One; 2017; 12(2):e0171272. PubMed ID: 28170419
[TBL] [Abstract][Full Text] [Related]
40. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
Horinaka S; Sugawara R; Yonezawa Y; Ishimitsu T
Br J Clin Pharmacol; 2018 Jan; 84(1):79-87. PubMed ID: 28888219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
